Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Speakers
All speakers are affiliated with Harvard Medical School
Kenneth Anderson, MD, BWH, Combination Targeted and Immune Therapies for Multiple Myeloma
Monica Bertagnolli, MD, BWH, Cancer Clinical Trials to Address Tumor Genomic Subsets
Joan Brugge, PhD, HMS, Cancer Therapy Resistance
George Demetri, MD, Dana-Farber, Mission Control from V-2 to Apollo: Combinations of Orthogonal Approaches to Overcome Cancer Resistance
Don Dizon, MD, MGH, Women’s Cancer and Survivorship
David Fisher, MD, PhD, MGH, Boosting Cancer Immunotherapy: Lessons from Melanoma
Keith Flaherty, MD, MGH, Precision Medicine Challenges for Targeted Therapy and Immunotherapy
Levi Garraway, MD, PhD, Dana-Farber, Improving Cancer Treatment through “Precision Medicine”
Jeffrey Golden MD, BWH, Cancer Diagnostics
Daniel Haber, MD, PhD, MGH, Blood Based Liquid Biopsies
Elizabeth Henske, MD, BWH, Dana-Farber, Tuberous Sclerosis/mTOR Signaling Pathway and New Developments Related to the Therapy of TSC, Lymphangioleiomyomatosis (LAM), and Other Rare Tumor Syndromes
Theodore Hong, MD, MGH, Advanced Radiation Therapy and other Technologies in Cancer Care
John Iafrate, MD, MGH, Molecular Diagnostics: Technology, Regulation, Reimbursement
Brian Crompton, MD, Dana-Farber, Breakthrough Cancer Technologies in Next Decade
Keith Joung, MD, PhD, MGH, CRISPR-Cas9 Genome Editing Technologies for Research and Therapeutics
Cigall Kadoch, PhD, Dana-Farber, Mammalian SWI/SNF (BAF) Complex Structure and Function in Human Cancer
Jeannie Lee, MD, PhD, MGH, Epigenetic Regulation and Intervention by Long Noncoding RNAs
Massimo Loda, MD, BWH, Novel Techniques in Molecular Pathology

• I was sitting at his Table
• discussion was on Imaging for Prostate Cancer

 

 
Jay Loeffler, MD, MGH, Introduction of New Technologies in Radiation Oncology: No Data, No Problem
Robert Martuza, MD, MGH, Oncolytic Viral Therapy of Cancer
Marcela Maus, MD, PhD, MGH, Cellular Immunotherapies
Ann Partridge, MD, Dana-Farber, Innovations in Cancer Survivorship
Scott Rodig, MD, PhD, BWH, Deciphering Bases of Anti-tumor Immunity through the Analysis of Primary Human Tumor Biopsy Specimens
Deborah Schrag, MD, BWH, Dana-Farber, Innovations in M-Health and E-health and Cancer Care: Realizing the potential of smart-trackers, smart-dispensers and smart-phones to deliver better cancer care
Arlene Sharpe, MD, PhD, BWH, Dana-Farber, Cancer Immunotherapy
Julie Silver, MD, Spaulding, Prehabilitation and Rehabilitation in High-Quality Cancer Care
Kimberly Stegmaier, MD, Dana-Farber, Toward More Precise Therapy for Children with Cancer: From Discovery to Translation
Guillermo Tearney, MD, MGH, In Vivo Microscopy Technologies for Cancer Diagnosis and Treatment
Ralph Weissleder, MD, PhD, MGH, Cancer Exosome Analysis
Jonathan Whetstine, PhD, MGH, Epigenetics, Tumor Heterogeneity and Acquired Resistance